Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity

  • Nat Nanotechnol. 2023 Dec 5. doi: 10.1038/s41565-023-01553-6.
Guangna Liu  #  1 ,  Nana Ma  #  1 ,  Keman Cheng  #  1 ,  Qingqing Feng  1 ,  Xiaotu Ma  1 ,  Yale Yue  1 ,  Yao Li  1 ,  Tianjiao Zhang  1 ,  Xiaoyu Gao  1 ,  Jie Liang  1 ,  Lizhuo Zhang  1 ,  Xinwei Wang  1 ,  Zhenhua Ren  2 ,  Yang-Xin Fu  2  3 ,  Xiao Zhao  4  5  6 ,  Guangjun Nie  7  8
Affiliations
  • 1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China.
  • 2. Changping Laboratory, Beijing, China.
  • 3. Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
  • 4. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China. [email protected].
  • 5. Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, China. [email protected].
  • 6. IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China. [email protected].
  • 7. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China. [email protected].
  • 8. Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, China. [email protected].
  • # Contributed equally.
PMID: 38052943 DOI: 10.1038/s41565-023-01553-6
Abstract

Trained immunity enhances the responsiveness of immune cells to subsequent infections or vaccinations. Here we demonstrate that pre-vaccination with bacteria-derived outer-membrane vesicles, which contain large amounts of pathogen-associated molecular patterns, can be used to potentiate, and enhance, tumour vaccination by trained immunity. Intraperitoneal administration of these outer-membrane vesicles to mice activates inflammasome signalling pathways and induces interleukin-1β secretion. The elevated interleukin-1β increases the generation of antigen-presenting cell progenitors. This results in increased immune response when tumour antigens are delivered, and increases tumour-antigen-specific T-cell activation. This trained immunity increased protection from tumour challenge in two distinct Cancer models.

Products